Panos Macheras is Emeritus Professor (since September 2014) of the Department of Pharmacy, University of Athens. He is the Founder (1of the Laboratory of Biopharmaceutics and Pharmacokinetics at the University of Athens. He established the PharmaInformatics Unit of the Research and Innovation Center ATHENA; he is currently the Head of the Unit.Adjunct Professor, Department of Pharmaceutical Sciences, State University of New York (SUNY), Buffalo, USA He received his B. Pharm. and Ph.D degree in Pharmaceutical Chemistry from the University of Athens, Greece. He also received a Ph.D degree in Biopharmaceutics-Pharmacokinetics from King's College, University of London, U.K. He has published more than 180 journal articles (more than 6500 citations, h=40) and seven books in the field of Biopharmaceutics-Pharmacokinetics-Pharmacodynamics. His research interests include experimental, theoretical and computational (modeling and simulation) studies on drugdissolution, release, gastrointestinal absorption, protein binding, drug-cyclodextrins interaction, bioequivalence, biopharmaceuitc classification of drugs, pharmacokinetics, fractal and fractional kinetics, applications of fractal concepts in biopharmaceutical systems and nonlinear dynamics. He serves on the Editorial Board of the journals, Pharmaceutical Research, International Journal of Pharmaceutics and European Journal of Pharmaceutical Sciences.

Expert discussion of rapidly expanding field of Pharmacokinetcs and Pharmacodynamics

Introduces for the first time the PBFTPK models and the reproducability concept in pharmaceutical sciences

Concise overview of advances in PK/PD modeling including COVID-19 information

¿Pharmacokinetics.- Chapter 1: Current status in PBPK modeling.- Chapter 2: Physiologically based biopharmaceutics modeling (PBBM) Application on Food Effect Assessment.- Chapter 3: Physiologically based finite time pharmacokinetic (PBFTPK) models: Inception and development.- Chapter 4: Physiologically based finite time pharmacokinetic (PBFTPK) models: Applications.- Pharmacodynamics.- Chapter 5: Pharmacokinetic - Pharmacodynamic Modelling and Simulation in Clinical Practice and Studies.- Chapter 6: On the Verge of Impossibility: Accounting for Variability Arising from Permutations of Comorbidities that Affect the Fate of Drugs in the Human Body.- Chapter 7: Impact of Clinical Pharmacology on the Modernization of Drug Development and Regulation.